Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
145.26(c) 146.5(c) 147.1(c) 147.84(c) 133(c) Last
6 848 441 9 857 360 8 869 173 6 008 330 57 946 380 Volume
-0.12% +0.85% +0.41% +0.50% -10.04% Change
More quotes
Financials (USD)
Sales 2018 81 339 M
EBIT 2018 25 408 M
Net income 2018 17 909 M
Debt 2018 9 928 M
Yield 2018 2,69%
Sales 2019 82 772 M
EBIT 2019 26 787 M
Net income 2019 20 410 M
Finance 2019 1 970 M
Yield 2019 2,85%
P/E ratio 2018 20,74
P/E ratio 2019 17,68
EV / Sales2018 4,51x
EV / Sales2019 4,29x
Capitalization 357 B
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (47.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses,... 
Sector
Pharmaceuticals
Calendar
01/22 | 12:45pmEarnings Release
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
12/16ASBESTOS IN JOHNSON & JOHNSON BABY P : Dubai mums, doctors cry foul
AQ
12/16JOHNSON & JOHNSON : What is talc, where is it used and why is asbestos a concern..
AQ
12/16JOHNSON & JOHNSON : hammered by report it knew of asbestos in baby powder
AQ
12/15JOHNSON AND JOHNSON PRODUCING DELIBE : Report
AQ
12/15JOHNSON & JOHNSON : Wall Street plummets amidst world recession fears
AQ
12/15JOHNSON & JOHNSON : Janssen Submits Supplemental New Drug Application (sNDA) to ..
AQ
12/15JOHNSON & JOHNSON : Global growth worries, J&J's tumble drag Wall St lower
AQ
12/14JOHNSON & JOHNSON : Business Highlights
AQ
12/14JOHNSON & JOHNSON : Hagens Berman Notifies Johnson & Johnson (JNJ) Investors of ..
PR
12/14WALL STREET STOCK EXCHANGE : Wall St. tumbles on global growth worries, J&J decl..
RE
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Sector news : Pharmaceuticals - NEC
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/14ELI LILLY AND : Lilly to Acquire Pre-Clinical Pain Program From Hydra Bioscience..
DJ
12/14THYSSENKRUPP : Incoming Thyssenkrupp CFO Will Prep Conglomerate for Split
DJ
12/14PFIZER : Raises Dividend, Authorizes New Share Repurchase Plan
DJ
12/14Merck bolsters animal health unit with $2.4 billion Antelliq purchase
RE
More sector news : Pharmaceuticals - NEC
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 148 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-4.81%356 703
PFIZER23.05%254 040
NOVARTIS5.61%223 295
ROCHE HOLDING LTD.1.38%216 307
MERCK AND COMPANY35.92%198 877
AMGEN10.45%122 391